Mück W, Wingender W, Seiberling M, Woelke E, Rämsch K D, Kuhlmann J
Institute of Clinical Pharmacology, Pharma Research Centre, Bayer AG, Wuppertal, FRG.
Eur J Clin Pharmacol. 1992;42(3):325-8. doi: 10.1007/BF00266356.
A possible interaction between the calcium antagonist nimodipine and the H2-receptor antagonists cimetidine and ranitidine has been investigated in two separate studies in healthy subjects. In eight young volunteers the concomitant administration of nimodipine 30 mg t.i.d. and cimetidine 1000 mg/d for 7 days led to a significant increase of the relative bioavailability of nimodipine. The changes in the pharmacokinetic parameters were not accompanied by discernible haemodynamic effects or any change in the tolerability of nimodipine. There was no evidence of any significant change in the steady-state pharmacokinetics of nimodipine during five days of combined treatment with 30 mg t.i.d. nimodipine and ranitidine 300 mg/d given as single morning dose to twelve healthy, elderly subjects. Analysis of haemodynamics, clinical chemistry and tolerance also did not reveal any difference between the two treatment periods.
在两项针对健康受试者的独立研究中,对钙拮抗剂尼莫地平和H2受体拮抗剂西咪替丁及雷尼替丁之间可能存在的相互作用进行了研究。在8名年轻志愿者中,连续7天每日3次给予尼莫地平30 mg并每日给予西咪替丁1000 mg,导致尼莫地平的相对生物利用度显著增加。药代动力学参数的变化并未伴随可察觉的血流动力学效应或尼莫地平耐受性的任何改变。在12名健康老年受试者中,连续5天每日3次给予尼莫地平30 mg并每日早晨单次给予雷尼替丁300 mg的联合治疗期间,未发现尼莫地平稳态药代动力学有任何显著变化。血流动力学、临床化学和耐受性分析也未显示两个治疗期之间存在任何差异。